Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Carina Frago"'
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2107-2116 (2021)
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Externí odkaz:
https://doaj.org/article/01e9265349dd42e8983c677b9b6022e8
Autor:
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Jing Jin, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 3, Pp 523-529 (2020)
The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participant
Externí odkaz:
https://doaj.org/article/2620c153eb504ca4901aa9243abdbc49
Autor:
Ngoc Huu Tran, Danaya Chansinghakul, Chia Yin Chong, Chian Yong Low, Lynette P. Shek, Chan Quang Luong, Carina Frago, T. Anh Wartel, Sunny Sun, Anna Skipetrova, Alain Bouckenooghe
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 10, Pp 2315-2327 (2019)
Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose o
Externí odkaz:
https://doaj.org/article/a0e26386e5e24f5cb85306817c238951
Autor:
Kriengsak Limkittikul, Weerawan Hattasingh, Danaya Chansinghakul, Arunee Sabchareon, Wut Dulyachai, Carina Frago, T Anh Wartel, Edith Langevin, Sophia Gailhardou, Alain Bouckenooghe
Publikováno v:
Asian Pacific Journal of Tropical Medicine, Vol 12, Iss 9, Pp 396-403 (2019)
Objective: To investigate the long-term safety of a tetravalent dengue vaccine (CYD-TDV) in children in a phase Π b follow-up study in Thailand. Methods: In the phase Π b study, children aged 4-11 years were randomized (2:1) to receive three inject
Externí odkaz:
https://doaj.org/article/e0464c7186f04e73b6d1a922a29000c4
Autor:
Chloé Pasin, M Elizabeth Halloran, Peter B Gilbert, Edith Langevin, R Leon Ochiai, Punnee Pitisuttithum, Maria Rosario Capeding, Gabriel Carrasquilla, Carina Frago, Margarita Cortés, Laurent Chambonneau, Zoe Moodie
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0207878 (2018)
OBJECTIVE:To evaluate the association of rainy season with overall dengue disease incidence and with the efficacy of the Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD-TDV) in two randomized, controlled multicenter phase III c
Externí odkaz:
https://doaj.org/article/2653ac996fa2487e9a0634a6e09fff9c
Autor:
Joshua Nealon, Anne-Frieda Taurel, Maria Rosario Capeding, Ngoc Huu Tran, Sri Rezeki Hadinegoro, Tawee Chotpitayasunondh, Chee Kheong Chong, T Anh Wartel, Sophie Beucher, Carina Frago, Annick Moureau, Mark Simmerman, Thelma Laot, Maïna L'Azou, Alain Bouckenooghe
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 8, p e0004918 (2016)
Dengue incidence has increased globally, but empirical burden estimates are scarce. Prospective methods are best-able to capture all severities of disease. CYD14 was an observer-blinded dengue vaccine study conducted in children 2-14 years of age in
Externí odkaz:
https://doaj.org/article/53e23409321b40968f81795331d0361c
Autor:
Osamu Matsuoka, Mugen Ujiie, Hitoshi Kikuchi, Sachiko Otake, Danaya Chansinghakul, Takahiro Inoue, Kucku Varghese, Nuchra Sirisuphmitr, Tomoyuki Hashiguchi, Betzana Zambrano, Takahiro Nakama, Carina Frago, Emilia Jordanov, Mandeep Singh Dhingra
Publikováno v:
Japanese Journal of Infectious Diseases. 76:174-182
Autor:
Peter B. Gilbert, Shida Shangguan, Fabrice Bailleux, Sanjay Gurunathan, Michal Juraska, Aviva Geretz, Christopher Bryant, Zoe Moodie, Shuying Sue Li, Kriengsak Limkittikul, Danaya Chansinghakul, Philip K. Ehrenberg, Wut Dulyachai, Richard G. Jarman, Nelson L. Michael, Alain Bouckenooghe, Carina Frago, Rasmi Thomas, Arunee Sabchareon, Weerawan Hattasingh
Publikováno v:
Human Immunology. 83:53-60
The recombinant, live, attenuated, tetravalent dengue vaccine CYD-TDV has shown efficacy against all four dengue serotypes. In this exploratory study (CYD59, NCT02827162), we evaluated potential associations of host human leukocyte antigen (HLA) alle
Autor:
Lynette Pei-Chi Shek, May-Lin Helen Oh, Matthew Bonaparte, Hao Wang, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon, Juliana Park, Frédérique Jantet-Blaudez, Sophia Archuleta, Alain Bouckenooghe, Carina Frago
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who comp
Autor:
Margarita Cortés, Laurent Coudeville, Clarence C. Tam, Denis Macina, Alain Bouckenooghe, Carina Frago, Joshua Nealon
Publikováno v:
The Journal of Infectious Diseases
Dengue endemicity varies but comparative, multicountry data are extremely limited. An improved understanding is needed to prioritize prevention, including vaccination, which is currently recommended only under specific epidemiological conditions. We